Effect of pulmonary surfactant and phospholipid hexadecanol tyloxapol on recombinant human-insulin absorption from intratracheally administered dry powders in diabetic rats

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 12, 2010, Pages 1612-1616

  Zheng, Jianheng ^a   Zhang, Ge ^a   Lu, Yang ^a   Fang, Fang ^a   He, Jiake ^a   Li, Ning ^a   Talbi, Amer ^a   Zhang, Ying ^a   Tang, Yue ^a   Zhu, Jiabi ^a   Chen, Xijing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Asborption enhancer; Lung delivery system; Phospholipid hexadecanol tyloxapol; Pulmonary surfactant; Recombinant human insulin

Indexed keywords

ACETYLGLUCOSAMINIDASE; ALKALINE PHOSPHATASE; GLUCOSE; HEXADECANOL; INSULIN; LACTATE DEHYDROGENASE; LUNG SURFACTANT; MANNITOL; PHOSPHOLIPID; RECOMBINANT HUMAN INSULIN; TYLOXAPOL;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRY POWDER; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; LUNG LAVAGE; LUNG TOXICITY; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

ABSORPTION; ACETYLGLUCOSAMINIDASE; ALKALINE PHOSPHATASE; ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION ROUTES; HUMANS; HYDRO-LYASES; HYPOGLYCEMIC AGENTS; INSULIN; LUNG INJURY; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; POWDERS; PULMONARY SURFACTANTS; RATS; RECOMBINANT PROTEINS; SURFACE-ACTIVE AGENTS; TIME FACTORS; TRACHEA;

EID: 78649843440     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.1612     Document Type: Article

References (23)

1. Kurmi B. D., Kayat J., Gajbhiye V., Tekade R. K., Jain N. K., Expert Opin. Drug Deliv., 7, 781-794 (2010).
2. Fisher A., Stegemann J., Scheuch G., Siekmeier R., Eur. J. Med. Res., 14 (Suppl. 4), 71-77 (2009).
3. Amidi M., Pellikaan H. C., de Boer A. H., Crommelin D. J. A., Hennink W. E., Jiskoot W., Eur. J. Pharm. Biopharm., 68, 191-200 (2008).
4. Courrier H. M., Butz N.,Vandamme T. F., Crit. Rev. Ther. Drug Carrier Syst., 19, 425-498 (2002).
5. Hussain A., Majumder Q., Ahsan F., Pharm. Res., 23, 138-147 (2006).
6. Dahlbäck M., Eirefelt S., Bäckström K., Larsson P., Almér L.-O., Wollmer P., Jonson B., J. Aerosol Med., 15, 27-36 (2002).
7. Todo H., Okamoto H., Iida K., Danjo K., Int. J. Pharm., 220, 101-110 (2001).
8. Hussain A., Arnold J. J., Khan M. A., Ahsan F., J. Controlled Release, 94, 15-24 (2004).
9. Jing Y., Liu C., Pei Y. Y., Acta Pharmacol. Sin., 28, 744-750 (2007).
10. Zhang Y., Zhu J., Tang Y., Chen X., Yang Y., Drug Dev. Ind. Pharm., 35, 1059-1065 (2009).
11. Enna S. J., Schanker L. S., Am. J. Physiol., 222, 409-414 (1972).
12. Antonini J. M., Murthy G. G. K., Rogers R. A., Albert R., Ulrich G. D., Brain J. D., Toxicol. Appl. Pharmacol., 140, 188-199 (1996).
13. Ritschel W. A., Ritschel G. B., Ritschel B. E., Lucker P. W., Methods Find. Exp. Clin. Pharmacol., 10, 645-656 (1988).
14. Çilek A., Çelebi N., TirnaksIz F., Tay A., Int. J. Pharm., 298, 176-185 (2005).
15. Yamamoto A., Umemori S., Muranishi S., J. Pharm. Pharmacol., 46, 14-18 (1994).
16. Takatsuka S., Morita T., Horikiri Y., Yamahara H., Saji H., Int. J. Pharm., 338, 87-93 (2007).
17. Mitra R., Pezron I., Li Y., Mitra A. K., Int. J. Pharm., 217, 25-31 (2001).
18. Nassimi M., Schleh C., Lauenstein H. D., Hussein R., Hoymann H. G., Koch W., Pohlmann G., Krug N., Sewald K., Rittinghausen S., Braun A., Müller-Goymann C., Eur. J. Pharm. Biopharm., 75, 107-116 (2010).
19. Nakate T., Yoshida H., Ohike A., Tokunaga Y., Ibuki R., Kawashima Y., Eur. J. Pharm. Biopharm., 55, 147-154 (2003).
20. Sakagami M., Adv. Drug Deliv. Rev., 58, 1030-1060 (2006).
21. Suzuki M., Machida M., Adachi K., Otabe K., Sugimoto T., Hayashi M., Awazu S., J. Toxicol. Sci., 25, 49-55 (2000).
22. Henderson R. F., Environ. Health Perspect., 56, 115-129 (1984).
23. Garcia-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., Newcomer C., Hickey A. J., Pharm. Res., 18, 1685-1693 (2001).